13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001993440
Total reported value
$934.7M
$934.7M
38 檔
15.2%
As reported in its official Q3 2024 Form 13F filing, First Turn Management, LLC's tracked investment portfolio stood at $934.7M with 38 total positions.
During Q3 2024, First Turn Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 5.82% | -3.89% | +42.35% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.67% | — | -31.93% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 4.12% | -1.53% | +10.23% | |
| 4 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.00% | -1.40% | -7.93% | |
| 5 | PCVX | Vaxcyte Inc | Stock-Other | 3.84% | +2.76% | NEW | |
| 6 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 3.63% | +2.16% | -24.30% | |
| 7 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.62% | — | +85.38% | |
| 8 | ASND | Ascendis Pharma A/S | Stock-Other | 3.56% | -1.95% | EXIT | |
| 9 | NTRA | Natera Inc | Stock-Healthcare | 3.13% | -1.81% | EXIT | |
| 10 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.95% | — | -26.64% | |
| 11 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.86% | — | -4.31% | |
| 12 | TMDX | Transmedics Group Inc | Stock-Healthcare | 2.84% | — | -18.27% | |
| 13 | ACLXGBX | Arcellx Inc | Stock-Other | 2.83% | — | — | |
| 14 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.62% | — | -3.23% | |
| 15 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.61% | — | — | |
| 16 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.59% | — | -30.52% | |
| 17 | BHVN | Biohaven Ltd. | Stock-Other | 2.50% | — | -13.72% | |
| 18 | ✓ | Establishment Labs Holdings In | Stock-Other | 2.45% | — | -3.51% | |
| 19 | ✓ | Merus N V | Stock-Other | 2.44% | — | -4.32% | |
| 20 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.35% | -0.52% | -4.28% | |
| 21 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.35% | — | -27.80% | |
| 22 | HROW | Harrow Inc | Stock-Other | 2.32% | — | — | |
| 23 | VERA | Vera Therapeutics Inc | Stock-Other | 2.28% | -1.90% | EXIT | |
| 24 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.27% | — | — | |
| 25 | GERN | Geron CORP | Stock-Other | 2.25% | — | — | |
| 26 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.16% | +2.45% | +29.49% | |
| 27 | ADMA | Adma Biologics Inc | Stock-Healthcare | 2.10% | — | — | |
| 28 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 2.09% | — | — | |
| 29 | RGEN | Repligen CORP | Stock-Healthcare | 2.09% | — | — | |
| 30 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.03% | -1.23% | -4.31% | |
| 31 | GKOS | Glaukos CORP | Stock-Healthcare | 1.98% | — | — | |
| 32 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.96% | — | -37.79% | |
| 33 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.87% | +2.72% | -23.92% | |
| 34 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.82% | — | +10.75% | |
| 35 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.61% | -0.72% | — | |
| 36 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.37% | — | — | |
| 37 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.36% | — | — | |
| 38 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.65% | — | -66.49% |
According to official SEC Form 13F filings, First Turn Management, LLC reported a total U.S. public equity portfolio value of $934.7M across 38 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, ARGX, INSM) accounted for 15.2% of total reported equity market value during Q3 2024.
During Q3 2024, First Turn Management, LLC's top holdings by market value included NUVL (5.8%)、ARGX (4.7%)、INSM (4.1%). The largest single position, NUVL, represented 5.8% of total portfolio value.
In Q3 2024, First Turn Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.